Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype.

Molecular cancer therapeutics - 1 Apr 2022

Preston Samuel E J, Emond Audrey, Pettersson Filippa, Dupéré-Richer Daphné, Abraham Madelyn Jean, Riva Alberto, Kinal Mena, Rys Ryan N, Johnson Nathalie A, Mann Koren K, Del Rincón Sonia V, Licht Jonathan D, Miller Wilson H

Abstract excerpt

Diffuse large B-cell lymphoma (DLBCL) accounts for 40% of non-Hodgkin lymphoma, and 30% to 40% of patients will succumb to relapsed/refractory disease (rrDLBCL). Patients with rrDLBCL generally have low long-term survival rates due to a lack of efficient salvage therapies. Small-molecule inhibitors targeting the histone methyltransferase EZH2 represent an emerging group of novel therapeutics that show promising...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enhancer of Zeste Homolog 2 Protein

Share to Indazoles

Share to Lymphoma, Large B-Cell, Diffuse

Share to Phenotype

Share to Pyridones

Source

Open in PubMed Open full text

Identifiers

PMID: 35086959
DOI: 10.1158/1535-7163.MCT-21-0216
PMCID: PMC8983450

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype.PMID 35086959Read ↗

Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas.Semantic proximity Read ↗

Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy ResistanceSemantic proximity Read ↗

Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas.Semantic proximity Read ↗

Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL).Semantic proximity Read ↗

Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell LymphomaSemantic proximity Read ↗

Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphomaSemantic proximity Read ↗

Histone Deacetylase Inhibitors: Emerging Mechanisms of ResistanceSemantic proximity Read ↗

Non-Hodgkin’s B-cell lymphoma: Advances in molecular strategies targeting drug resistanceSemantic proximity Read ↗

Mechanisms of chemoresistance in diffuse large B‑cell lymphoma and novel therapeutic strategies (Review).Semantic proximity Read ↗

Recurrent Mutations in Refractory/Relapsed Diffuse Large B-Cell Lymphoma by Targeted Gene Sequencing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.